Responses to Pure Antiestrogens (ICI 164384, ICI182780) in Estrogen‐Sensitive and‐Resistant Experimental and Clinical Breast Cancer

Annals of the New York Academy of Sciences

Volumn 761, Issue 1, 1995, Pages 148-163

  NICHOLSON, R I ^a   GEE, J M W ^a   MANNING, D L ^a   WAKELING, A E ^b   MONTANO, M M ^c   KATZENELLENBOGEN, B S ^c  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PROLACTIN; TAMOXIFEN; UNCLASSIFIED DRUG; ZM 163613;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CANCER REGRESSION; CANCER RESISTANCE; CELL GROWTH; CELL STRAIN MCF 7; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN CELL; META ANALYSIS; PHASE 1 CLINICAL TRIAL; PROLACTIN BLOOD LEVEL;

EID: 0029077113     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1995.tb31376.x     Document Type: Article

References (62)

1. The future of pure antioestrogens in clinical breast cancer
2. Pure antioestrogens (ICI164384 and ICI 182780) and breast cancer: Is the attainment of complete oestrogen withdrawal worthwhile
3. A comparative study of the interaction of oestradiol and the steroidal pure antioestrogen, ICI 164384 with molybdate stabilized oestrogen receptor
4. Steroidal pure antioestrogens
5. Pure antioestrogens in breast cancer: experimental and clinical observations
6. Investigation of a new pure antioestrogen (ICI 182780) in women with primary breast cancer
7. Points of action of estrogen antagonists and a calmodulin antagonist within the MCF‐7 human breast cancer cell cycle
8. Effects of antioestrogens on the proliferation of MCF‐7 human breast cancer cells
9. Estrogen deprivation in breast cancer: clinical, experimental and biological aspects
10. Effects of the antioestrogen, ICI 164384, on oestrogen induced mRNAs in MCF‐7 cells
11. Effect of estrogen and antioestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF‐7 and a tamoxifen resistant variant subline, AL‐1
12. R‐l
13. Isolation of pMGTl: a gene that is repressed by oestrogen and increased by antioestrogens and antioprogestins
14. Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by oestradiol and its possible functional significance
15. Immunocytochemical localisation of BCL‐2 protein in human breast cancer and its relationship to a series of prognostic markers and response to endocrine therapy
16. Ki67 immunostaining in primary breast cancer: pathological and clinical associations
17. Immunocytochemical localisation of oestrogen and progesterone receptors
18. Novel antioestrogens without partial agonistic activity
19. A potent specific pure antiestrogen with clinical potential
20. Pure antioestrogens and breast cancer
21. The mechanism of ICI164384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue
22. Antiestrogen ICI 164384 reduces cellular estrogen receptor content by increasing its turnover
23. Inhibition of estrogen receptor‐DNA binding by the pure antioestrogen ICI 164384 appears to be mediated by impaired receptor dimerisation
24. Estrogen receptor synthesis and turnover in MCF‐7 breast cancer cells measured by a density shift technique
25. Recent data on estrogen sulfatases and sulphotransferases activities in human breast cancer
26. Estrone sulfate promotes human breast cancer cell replication and nuclear uptake of estradiol in MCF‐7 cell cultures
27. Estrone sulfamates: potential inhibitors of estrone sulfatase with therapeutic potential
28. Effect of promegestone, tamoxifen, 4‐hydrodoxytamoxifen and ICI 164384 on the oestrone sulphatase activity of human breast cancer cells
29. Role of insulin‐like growth factors and type I insulin‐like growth factor receptor in the estrogen‐stimulated proliferation of human breast cancer cells
30. Modulation of proliferative response of breast cancer cells to growth factors by oestrogen
31. IGFs and control of cell proliferation in breast and other cancers
32. Coupling of dual signalling pathways: epidermal growth factor action involves the estrogen receptor
33. Inhibition of EGF‐receptor tyrosine kinase activity by 4‐aniloquinazolines
34. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor
35. Dopaminergic and ligand‐independent activation of steroid hormone receptors
36. Transforming growth factor α and endocrine sensitivity in breast cancer
37. Human breast cancer in the athymic mouse: cytostatic effects of long‐term antiestrogen therapy
38. The importance of tamoxifen metabolism in tamoxifen‐stimulated growth. Cancer Chemother
39. Development of tamoxifen‐stimulated growth of MCF‐7 tumours in athymic mice after long‐term antioestrogen administration
40. Progression of breast cancer cells from hormone dependent to hormone independent growth both in vitro and in vivo. Proc
41. Heterogeneity of progesterone receptor content and remodelling by tamoxifen characterise subpopulations of cultured human breast cancer cells: analysis by quantitative dual parameter flow cytometry
42. Resistance to 40H‐tamoxifen does not confer resistance to the steroidal antioestrogen ICI 182780, while acquired resistance to ICI 182780 results in cross‐resistance to 40H‐tamoxifen
43. Selection and characterization of breast cancer cell line resistant to the antiestrogen LY 117018
44. Hormone resistance, invasiveness, and metastatic potential in breast cancer. Breast Cancer Res
45. Inhibition of tamoxifen‐stimulated growth of an MCF‐7 tumour variant in athymic mice by novel steroidal antiestrogens
46. Inflammatory breast carcinoma: an immunohistochemical study using anti‐pHER‐2/neu, pS2, cathepsin, ER and PR
47. Immunocytochemical localisation of estrogen receptor in human breast cancer
48. Examination of the DNA‐binding ability of ER in whole cells: implications for hormone independent transactivation and the actions of antioestrogens
49. Proliferation, hormonal responsiveness and estrogen receptor content of MCF‐7 human breast cancer cells grown in the short‐term and long‐term absence of estrogens
50. Differential regulation of gene expression by estrogen in estrogen growth‐independent and ‐dependent MCF‐7 human breast cancer cell sublines
51. The 5′‐flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the c‐Ha‐ras oncoprotein and the c‐jun protein
52. Tamoxifen as an agonist for metastatic breast cancer
53. Response after withdrawal of tamoxifen and progestins in advanced breast cancer
54. Response in breast cancer to a second hormonal therapy
55. Multicenter Phase II efficacy trial of toremifene in tamoxifen‐refractory patients with advanced breast cancer
56. Recent advances in the antihormonal therapy of breast cancer
57. New antihormonal approaches to breast cancer therapy